Inhibition of thromboxane synthase （TXAS）， especially in human platelets， has been a clinical objective for many years. 1-Alkyl （N-alkyl）-imidazole derivatives have been recognized as TXAS inhibitors since the early 1980s. Ozagrel is a 1-alkyl imidazole derivative that acts as a selective inhibitor of TXAS with an IC50 of 11 nM. The beneficial effects of TXAS inhibition by ozagrel include improved motor coordination after experimental stroke， and antihypertensive effects in spontaneously hypertensive rats.
产品描述
A selective inhibitor of TXA synthase （IC50 = 11 nM）
